N2CR is proud to announce that our primary member, Dr Stephen Chong, has been awarded the 2025 ASH Abstract Achievement Award for his abstract titled ‘CD47‑blockade induces programmed necroptosis and complements the effects of BCL‑2 inhibition in lymphoid malignancies’. He will be presenting is abstract at the 67th ASH Annual Meeting & Exposition, taking place from December 6–9, 2025 in Orlando, Florida.

Dr Chong’s achievement reflects not only his dedication but also N2CR’s unwavering commitment to advancing cancer research and driving innovation for better patient outcomes.